Press Releases

 Filter by Provider

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that preliminary results from an investigator-sponsored study evaluating botensilimab (BOT) in combination with balstilimab (BAL) in first-line microsatellite stable colorectal cancer (MSS CRC) will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 18–23 in San Diego, CA.

KASTAMONU, Türkiye - March 17, 2026 - Spontane Media Kastamonu, an independent digital media initiative founded by Turkish journalism student Berat Kaan Yılmaz, continues to expand its international media presence through global press distribution platforms while promoting local journalism and regional storytelling.

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against NuScale Power Corporation (“NuScale” or the “Company”) (NYSE: SMR).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

Within the rarefied sphere of Fort Lauderdale architects, architecture becomes less about construction and more about authorship—an intellectual territory reserved for those who understand that space is a language through which power is quietly articulated. Studio KHORA operates precisely in this domain. Here, architecture is not decoration, but discourse: a system of signs, absences, and controlled tensions that allow each residence to emerge as a singular statement of identity. The house is no longer an object. It becomes a text—read, interpreted, and ultimately possessed.

A new report from Belitsoft, a company that specializes in custom software development, shows how U.S. companies are using strategic outsourcing to find senior PHP developers, save up to 60% on costs, and speed up time-to-market with Laravel 13 and PHP 8.3+.

Full Alliance Group (OTCQB: FAGI) continues executing its multi-vertical growth strategy as its subsidiary Aquaox Pure Solutions, LLC reports accelerating marketplace traction for JusSpray™, the company’s flagship hypochlorous acid (HOCl) skin defense spray.

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced three of the Company’s internally-developed investigational oncology therapies will be presented across four poster sessions at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2026 taking place April 17-22 in San Diego, California. These next-generation candidates include: zocilurtatug pelitecan (zoci, formerly ZL-1310), a DLL3-targeting antibody-drug conjugate (ADC) for small cell lung cancer (SCLC); ZL-6201, a leucine-rich repeat-containing protein 15 (LRRC15) ADC for the treatment of sarcoma and epithelial tumors with LRRC15 expressing cancer-associated fibroblasts (CAFs); and, ZL-1222, a PD-1 and interleukin-12 (IL-12) signaling attenuated mutein agonist immunocytokine for cancer immunotherapy.

SAN DIEGO and SUZHOU, China, March 17, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that muzastotug will be highlighted in two poster presentations at this year’s AACR Meeting, taking place April 17-22 in San Diego, CA.

Synthekine Inc., an engineered cytokine therapeutics company, today announced that updated clinical and translational data from a Phase 1a/1b clinical trial of its α/β biased IL-2 partial agonist, STK-012, will be presented in an oral presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2026 taking place in San Diego, CA from April 17 - 22, 2026. In this now fully enrolled study, STK-012 is being evaluated in combination with standard-of-care pembrolizumab + chemotherapy in first-line nonsquamous (NSQ) non-small cell lung cancer (NSCLC) patients with features of immune resistance such as PD-L1 negative histology and STK11/KEAP1 mutations.

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced it will present a poster on one of the three key mechanisms by which atebimetinib aims to improve overall survival: shrinking tumors durably. The poster will be presented at the American Association for Cancer Research (AACR) Annual Meeting taking place April 17-22, 2026 in San Diego, CA.

UK - Mar 17, 2026 - EarpieceOnline.co.uk has highlighted a growing need for discreet, high-quality communication tools across the retail, hospitality, and event sectors. With customer-facing teams requiring rapid communication that does not disrupt the customer experience, modern alternatives to traditional acoustic tubes, such as the Resowire earpiece, are increasingly becoming a frontline essential.

It is the quiet dread of every professional artist.You spend weeks on a commission. The brushwork is perfect. The client is thrilled. You ship the piece, confident that your work is done. But two months later, you get the email that makes your stomach drop. "The painting... it looks twisted."

UnitedHealth Group (NYSE: UNH) will release its first quarter 2026 financial results on Tuesday, April 21, 2026, before the market opens, and will host a teleconference at 8:00 a.m. ET with analysts and investors. This call will be webcast on the Investor Relations page of the company’s website (www.unitedhealthgroup.com). The replay will be available through May 5, 2026, on the website.

ST. GALLEN, Switzerland, March 17, 2026 (GLOBE NEWSWIRE) -- Sportradar Group AG (Nasdaq: SRAD) (“Sportradar” or the “Company”), a leading global sports technology company focused on creating immersive experiences for sports fans and bettors, today announced that Craig Felenstein, the Company’s Chief Financial Officer, will participate in the 38th Annual Roth Conference on Tuesday, March 24th, 2026. The fireside chat will take place at 1:30 pm eastern time. The webcast can be accessed at investors.sportradar.com.

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Ostin Technology Group Co., Ltd. (“Ostin” or the “Company”) (NASDAQ: OST).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

Texas King Haul LLC, a Houston-based dump truck and material delivery company, is expanding its services across the Greater Houston construction market with the goal of helping builders, contractors, developers, and property owners access reliable hauling and construction material solutions. The company aims to increase visibility for essential services such as dirt haul-off services, sand delivery, select fill delivery, and dump truck services in Houston.

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced the completion of the acquisition of Bako Diagnostics, a premier pathology laboratory, and StrataDx, a premier dermatopathology laboratory, as previously announced on December 22, 2025.

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced four presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting highlighting new data in molecular residual disease (MRD) testing and multi-cancer early detection (MCED). The meeting will take place from April 17–22, 2026, in San Diego, CA.

WILMINGTON, Del., March 17, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced that a poster with preclinical data on the Company’s oral KAT6A selective degrader (PRT13722) has been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place from April 17-22.

Cambridge, MA - March 17, 2026 - Thrawn, a healthcare logistics startup, today announced the general availability of its managed physician scheduling service for residency and fellowship programs . The service uses a proprietary mathematical optimization engine to generate complete Block, Call, Clinic, and Attending schedules — eliminating the hundreds of hours chief residents and program directors currently spend building schedules manually in spreadsheets.

VANCOUVER, BC, March 17, 2026 – TheNewswire - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or the “Company”) is providing this bi-weekly update on the status of the management cease trade order granted on March 3, 2026 (the “MCTO”), by its principal regulator, the British Columbia Securities Commission (the “BCSC”) under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203”). The Company announced on March 3, 2026 (the “Default Announcement”), that it was unable to file its audited annual financial statements for the year ended October 31, 2025, the related management’s discussion and analysis, and its Form 52-109FV1 CEO and CFO certifications of annual filings (collectively the “Annual Filings”). Under National Instrument 51-102 - Continuous Disclosure Obligations, the Annual Filings were required to be made not later than February 28, 2026.

Oklo Inc. (NYSE: OKLO) (“Oklo”), an advanced nuclear technology company, today announced the U.S. Department of Energy (DOE) has approved the Nuclear Safety Design Agreement (NSDA) for Atomic Alchemy’s Groves Isotopes Test Reactor in Texas under the DOE’s Reactor Pilot Program (RPP).

Beazer Homes USA, Inc. (the “Company”) (NYSE: BZH) announced that it has entered into a third amendment to its existing senior unsecured revolving credit facility (“Credit Facility”) that increased the available aggregate commitment amount by $160 million to $525 million. The amendment also extends the maturity date of the Credit Facility from March 15, 2028 to March 13, 2030.

Frontier Medicines Corporation, a clinical-stage precision medicines company unlocking the proteome to develop small molecule oncology and immunology drugs against previously undruggable disease-causing targets, today announced that it will present preclinical data on its FMC-242 program, as well as advances from its AI-powered Frontier™ Platform, at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22, 2026, in San Diego. FMC-242 is Frontier’s first-in-class allosteric breaker of the PI3Kα-RAS interaction that is in preclinical development for the treatment of solid tumors driven by RTK activation, RAS mutations and PI3Kα mutations, as both a single agent and in combination with other therapies including KRAS inhibitors.

Ceramic, an AI-native search infrastructure company, today unveiled Supervised Generation at NVIDIA GTC 2026 — a system that augments large language model (LLM) outputs with real-time verification, citations and confidence signals. Supervised Generation is model-agnostic, operating as a trust layer alongside any existing LLM infrastructure, with NVIDIA Nemotron 3 Nano as the featured verification engine. To sign up for our waitlist, visit ceramic.ai, or visit us March 16-19 at booth #4035.

Pheast Therapeutics, a clinical-stage biotechnology company advancing macrophage-directed immunotherapies for cancer, today announced that it will present three abstracts at the American Association for Cancer Research® (AACR) Annual Meeting 2026, taking place April 17–22 in San Diego.

SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biopharmaceutical company focused on the design and development of next-generation medicines for cancer, today announced it will introduce its next-generation KRAS pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2026. These two non-covalent pan-KRAS inhibitors leverage a differentiated chemical scaffold to address limitations of contemporary molecules - achieving sub-nanomolar potency and a prolonged off-rate, combined with oral bioavailability. In addition, the company will present new preclinical data supporting the continued advancement of its clinical programs BH-30643, a first-in-class, mutant-selective, macrocyclic OMNI-EGFRTM inhibitor, and BH-30236, an oral CLK inhibitor for hematologic malignancies. The AACR Annual Meeting 2026 will be held April 17-22, 2026, in San Diego. 

Akamis Bio, a clinical-stage oncology company working to advance the standard of care in colorectal cancer, today announced an upcoming poster presentation of initial clinical data from the FORTRESS study of NG-350A, an oncolytic immunotherapy for the treatment of mismatch repair-proficient (pMMR) locally advanced rectal cancer (LARC), at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22 in San Diego.

SingleCell Biotechnology, a biotechnology company developing technologies to measure tumor cell behavior at single-cell resolution, today announced that data from its platform will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, to be held in San Diego, April 17-21, 2026.

Soley Therapeutics, a biotechnology company advancing novel therapeutics informed by integrated cell stress biology, today introduced STX-6398, a first-in-class drug candidate with selective anti-tumor activity through modulation of cytoskeleton-associated protein 2 (CKAP2), a previously undruggable protein central to malignant cancer progression. Preclinical data for STX-6398 will be presented at the American Association for Cancer Research® (AACR) Annual Meeting 2026, taking place April 17-22 in San Diego.

Onchilles Pharma, a private biotech company advancing therapeutics targeting the ELANE pathway, today announced that new preclinical data supporting its systemically delivered NEU-002 program will be presented at the American Association for Cancer Research® (AACR) Annual Meeting 2026, taking place April 17-22 in San Diego. The presentation will highlight the translational development of NEU-002, an engineered therapeutic elastase specifically designed for systemic administration, demonstrating anti-tumor activity via both intravenous and intraperitoneal delivery in solid tumors.

Orum Therapeutics (“Orum” or the “Company”) (KRX: 475830), a biotechnology company pioneering the field of degrader antibody conjugates (DACs), today announced that new preclinical data on ORM-1153, a CD123-targeting DAC designed to selectively deliver a proprietary GSPT1-degrading payload for the treatment of acute myeloid leukemia (AML), will be presented at the American Association for Cancer Research® (AACR) Annual Meeting 2026, taking place April 17-22 in San Diego.

CHANTILLY, Va., March 17, 2026 (GLOBE NEWSWIRE) -- Today, Parsons Corporation (NYSE: PSN) announced a planned transition in its human resources function leadership, promoting Soo Lagasse to chief human resources officer (CHRO), effective April 1, 2026. Lagasse, who currently serves as senior vice president of global talent acquisition and mobility at Parsons, succeeds Susan Balaguer, who notified Parsons’ CEO and board of directors of her intent to retire this spring. Balaguer will remain with Parsons through the end of May to ensure a seamless transition.

FRANKFURT AM MAIN, Germany, March 17, 2026 (GLOBE NEWSWIRE) -- Anbio Biotechnology (NASDAQ: NNNN) ("Anbio" or the "Company"), a global diagnostic company in in-vitro diagnostic (IVD) technologies, announced today that its CEO will participate in the upcoming KeyBanc Capital Markets Virtual Healthcare Forum on Wednesday, March 18, 2026.

SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today announced that on March 16, 2026 the Company’s Compensation Committee of the Board of Directors (the “Compensation Committee”) granted equity awards to two newly hired employees in the form of restricted stock units (“RSUs”) and non-qualified stock options (“NSOs”) for an aggregate of 38,442 RSUs and 43,000 NSOs as an inducement material to their acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The employment inducement awards were granted under the Company’s 2025 Inducement Plan.

Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting

CALGARY, Alberta, March 17, 2026 (GLOBE NEWSWIRE) -- TransAlta Corporation (TransAlta or the Company) (TSX: TA) (NYSE: TAC) confirms that its subsidiary, TransAlta Centralia Generation LLC, has received an order (The Order) from the United States Department of Energy. The Order mandates that Centralia Unit 2 in Washington State remain available for operation, for a period of 90 days, until June 14, 2026.

CALGARY, Alberta, March 17, 2026 (GLOBE NEWSWIRE) -- Further to TransAlta Corporation's (TransAlta or the Company) (TSX: TA) (NYSE: TAC) press release dated March 2, 2026, the Company announced today that none of its 9,629,913 currently outstanding Cumulative Redeemable Rate Reset First Preferred Shares, Series A (Series A Shares) will be converted on March 31, 2026, on a one-for-one basis, into Cumulative Redeemable Floating Rate First Preferred Shares, Series B (Series B Shares), and (ii) 1,148,549 of its 2,370,087 currently outstanding Series B Shares will be converted on March 31, 2026, on a one-for-one basis, into Series A Shares. As a result, on March 31, 2026, the Company will have 10,778,462 Series A Shares issued and outstanding and 1,221,538 Series B Shares issued and outstanding.

SAN FRANCISCO, March 17, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced it will present two preclinical posters at the American Association for Cancer Research (AACR) Annual Meeting taking place April 17-22 in San Diego, California.

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced it will present three posters at the American Association for Cancer Research (AACR) 2026 Annual Meeting, taking place April 17-22 in San Diego, California, USA.

Robert August, a renowned name in handcrafted footwear, is proud to announce the latest addition to its esteemed casual sneaker collection: The Berwyn Ave. Knit Trainer. This lightweight, modern sneaker is engineered for all-day comfort and effortless style, setting a new standard for casual footwear.

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Masonite International Corporation (“Masonite” or the “Company”). (NYSE: DOOR) Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

In global travel hubs, car rental counters have long been dominated by multinational operators managing capital-intensive fleets financed through debt-heavy balance sheets. But in high-seasonal tourist markets such as Spain’s Canary Islands, a different model is quietly gaining traction — one that relies on digital coordination rather than vehicle ownership.

A major crash can change your life in a matter of seconds. One moment you are driving through Charlotte on your usual route, and the next you are dealing with ambulance rides, hospital visits, and calls from insurance adjusters. When injuries are serious, the stress can feel overwhelming. Medical bills start arriving quickly, work may be put on hold, and it becomes hard to know who to trust or what steps to take next.

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against uniQure N.V. (“uniQure” or the “Company”) (NASDAQ: QURE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

Several large cannabis companies operating across multiple U.S. states collectively owe over $1.6 billion in unpaid federal taxes, according to information disclosed in recent corporate filings. The outstanding balances stem largely from disputes over Internal Revenue Code Section 280E, a provision that significantly limits the deductions marijuana businesses can claim.

Several large cannabis companies operating across multiple U.S. states collectively owe over $1.6 billion in unpaid federal taxes, according to information disclosed in recent corporate filings. The outstanding balances stem largely from disputes over Internal Revenue Code Section 280E, a provision that significantly limits the deductions marijuana businesses can claim.

Sixth Street Specialty Lending, Inc. (NYSE: TSLX, or the “Company”) today sent the following letter to its stakeholders.

San Jose, Calif. - March 17, 2026 - Ecosense®, a global leader in radon detection and monitoring technology, today announced a new partnership with Citizens for Radioactive Radon Reduction (CR3) , a nonprofit organization dedicated to reducing radon-related health risks through education, advocacy, and community-based action. Together, Ecosense and CR3 will expand access to professional-grade digital radon monitors by supporting and growing library lending programs across the United States.

The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Camping World Holdings, Inc. (NYSE: CWH) securities between April 29, 2025 and February 24, 2026, both dates inclusive (the “Class Period”), have until May 11, 2026 to seek appointment as lead plaintiff of the Camping World class action lawsuit. Captioned Siverd v. Camping World Holdings, Inc., No. 26-cv-02710 (N.D. Ill.), the Camping World class action lawsuit charges Camping World as well as certain of Camping World’s top current and former executive officers with violations of the Securities Exchange Act of 1934.